Cytoreductive Surgery with HIPEC
Cross-source consensus on Cytoreductive Surgery with HIPEC from 1 sources and 3 claims.
1 sources · 3 claims
Uses
How it works
Risks & contraindications
Highlighted claims
- CRS combined with HIPEC is described as the established standard of care for peritoneal metastases from gastrointestinal and gynaecological cancers and mesothelioma. — Efficacy of intraoperative use of 20% albumin in combination with Ringer’s lactate versus Ringer’s lactate during cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: protocol for a randomised controlled, open-label clinical trial (ALBUCHIP trial)
- CRS with HIPEC creates major intraoperative fluid shifts because of surgical resection, peritoneal inflammation, and increased capillary permeability. — Efficacy of intraoperative use of 20% albumin in combination with Ringer’s lactate versus Ringer’s lactate during cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: protocol for a randomised controlled, open-label clinical trial (ALBUCHIP trial)
- Both intraoperative hypovolemia and volume overload are associated with poor postoperative outcomes in this setting. — Efficacy of intraoperative use of 20% albumin in combination with Ringer’s lactate versus Ringer’s lactate during cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: protocol for a randomised controlled, open-label clinical trial (ALBUCHIP trial)